Open App
you are here:

Wyeth Ltd.

BSE Live

Dec 09, 16:00
1334.60 0.00 (0.00%)
Volume
No Data Available
0
  • Prev. Close

    1334.60

  • Open Price

    1395.90

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    0.00 (0)

Wyeth is not traded on BSE in the last 30 days

NSE Live

Dec 09, 15:52
1333.85 0.00 (0.00%)
Volume
No Data Available
0
  • Prev. Close

    1333.85

  • Open Price

    1372.00

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    0.00 (0)

Wyeth is not traded on NSE in the last 30 days
Company History - Wyeth
1947
 
 - The Company was incorporated on 20th September under the name
 Lederle Laboratories (India) Ltd. as a private limited company.  The
 name was changed to Cyanamid India Ltd., on 31st October, 1962.  It
 became a full fledged public limited company in November 1965.  The
 Company Manufacture drugs, pharmaceuticals and agro-chemicals,
 insecticides and animal health products.  Initially, the Company was
 a
 wholly owned subsidiary of American Cyanamid Co., U.S.A.
 
 1961
 
 - A basic fermentation plant was built, for the manufacture, mainly
 from indigenous raw materials, of the basic bulk drugs required for
 the
 formulations of the Lederle antibiotics, viz., Aureomycin,
 Achromycin
 and Ledermycin.
 
 1962
 
 - The Atul Products Ltd., Ahmedabad acquired by subscribing to a
 fresh
 issue of share, a 24% interest which was increased (also by
 subscription to fresh issue of shares) to 35% in 1963.
 
 1963
 
 - The Agricultural division's malathion insecticide plant at Atul,
 Valsad was commissioned.  A wide range of pesticides as well as
 animal
 health products were introduced thereafter.
 
 1964
 
 - Since incorporation upto the end of the year, the Company issued
 the
 following shares:
 
 - (i) 1,502 No. of Equity shares of Rs 100 each for cash at par to
 American Cyanamid Co. U.S.A., in 1947,
 
 - (ii) 15,160 No. of equity shares of Rs 100 each without payment in
 cash to American Cyanamid Co., U.S.A., in 1953,
 
 - (iii) 894 No. equity shares of Rs 100 each without payment in cash
 to
 American Cyanamid Co., U.S.A., in 1961,
 
 - (iv) 10,329 No. of Equity shares of Rs 100 each at a premium of Rs
 163.89 per shares to The Atul Products Ltd., during 1961 and 1962,
 
 - (v) 997 No. of Equity shares of Rs 100 each without payment in
 cash
 to American Cyanamid Co., U.S.A., in 1962,
 
 - (vi) 13,482 No. of Equity shares of Rs 100 each at a premium of Rs
 55.80 per share to The Atul Products Ltd., and 12,884 No. of equity
 shares of Rs 100 each without payment in cash to American Cyanamid
 Co.,
 U.S.A., in 1963 and
 
 - (vii) 740 No. of Equity shares of Rs 100 each for cash in 1964.
 
 1974
 
 - 70,146 bonus shares issued on 18.3.1975 in prop. 1:1.
 
 1979
 
 - During June, the Company offered for sale 6,83,924 No. of Equity
 shares (4,55,949 No. of Equity shares held by American Cyanamid Co.,
 U.S.A. and 2,27,975 No. of Equity shares held by the Atul Products
 Ltd.) Rs 10 each at a premium of Rs 12 per share to the resident
 Indian
 nationals.  Out of these shares, 30,000 shares were reserved for
 subscription by the employees of the Company and 6,53,924 shares
 offered to the public.  After the offer for sale, the
 inter-connections
 of the Company with The Atul Products Ltd., was severed under the
 MRTP
 Act.
 
 - 3,15,657 bonus shares issued on 12.1.1979 in prop. 9:4.  Shares
 subdivided on 22.1.1979.  Authorised capital increased effective
 from
 21.2.1979.
 
 1981
 
 - The products manufactured in organophosphate plant were THIMET,
 ABATE and ACCOTHION.
 
 1987
 
 - During September-October, out of its holding of 25,07,721 No. of
 equity shares in the Company, the American Cyanamid Co., U.S.A.,
 offered to the resident Indian nationals 4,08,221 No. of Equity
 shares
 at a premium of Rs 20 per share to reduce its holding in the
 Company.
 These shares were offered as follows:
 
 - (i) 2,60,304 shares to the existing resident Indian equity
 shareholders excluding Gujarat Industrial and Investment Corporation
 Ltd., and Ameer Trading Corporation Ltd.,
 
 - (ii) 78,696 shares to the shareholders of Atul Products Ltd.,
 
 - (iii) 50,000 shares to UTI and
 
 - (iv) 19,221 shares to business associates of the Company.
 
 - The Company issued 6,90,510 No. of equity shares at a premium of
 Rs
 20 per share to the resident Indian nationals simultaneously with
 the
 offer for sale of shares during September-October is as follows:
 
 - (i) 2,18,443 shares to resident Indian equity shareholders
 excluding
 Gujarat Industrial & Investment Corporation Ltd., and Ameer Trading
 Corporation Ltd.,
 
 - (ii) 4,37,542 shares to shareholders of Atul Products Ltd., and
 
 - (iii) 34,525 shares to employees (including Indian working
 directors/workers of the Company.  Thus along with the offer for
 sale,
 a total of 4,78,747 shares were offered as rights to the
 shareholders
 in proportion 7:10 besides offer to the other categories.
 
 1988
 
 - A new 45KL stainless steel fermentor was installed.  A new
 antibiotic
 cynomycin and a pediatric suspension Penetrin were introduced.
 
 - The Company obtained a licence for manufacture of two million
 cynomycin capsules.
 
 1989
 
 - An industrial licence was received in February for the manufacture
 of
 150 tonnes of aeropromoter flocullants and collectors.
 
 1990
 
 - PROTON an effective herbicide was launched by the crop protection
 chemicals division.
 
 - Government approval was received for the manufacture of loxapine
 (an
 anti-psychotic agent).
 
 1994
 
 - The Agricultural products division launched Azodrin and Ripcord in
 the agrochemical market.  A new product by the name Tussivil (cough
 syrup) was launched.
 
 1996
 
 - Approvals were received for the scheme for arrangement between
 Cyanamid Agro Ltd. & Cyanamid India Ltd., and also for Wyeth
 Laboratories Ltd., John Wyeth (India) Ltd. and Wyeth (India) Ltd in
 the
 Cyanamid India Ltd.  The scheme became effective from September 12,
 1997 and the Agro undertaking of the company was to be transferred
 to
 and vested in Cyanamid Agro Ltd.  On amalgamation of Wyeth Companies
 with the company, the name of the Company changed to Wyeth Lederle
 Ltd.
 
 1997
 
 - Cyanamid India Limited, Cyanamid Agro Limited and the three Wyeth
 companies are being amalgamated with a view to bifurcating their
 business into two areas, agricultural products and pharmaceutical
 products under two companies.
 
 - The Scheme of Amalgamation will position Wyeth Lederle Limited as
 the
 tenth largest pharmaceutical company in India.
 
 1998
 
 - Wyeth Lederle India will be adding an anti-meningitis vaccine to
 its
 drugs portfolio.  The vaccine, expected to be launched in a month,
 will
 combat HIB meningitis.
 
 - The company launched a vaccine for meningitis which is witnessing
 a
 35 per cent plus growth rate.
 
 1999
 
 - Pharmaceutical major, Wyeth Lederle, is expanding its vaccines
 business as the company is currently set to launch new vaccines in
 India.  The company had recently launched Pnu-Immune 23, a product
 to
 counters bacteria causing Pn.
 
 - Pharma multinational Wyeth Lederle is exploring the possibility of
 setting up a greenfield unit for manufacturing formulations.
 
 - The Company has two manufacturing facilities in Valsad (Gujarat)
 and
 Ghatkopar (Maharashtra).
 
 2000
 
 - Wyeth Lederle and Cyanamid Agro are subsidiaries of the American
 Home
 Products Corporation.
 
 - Wyeth has two manufacturing facilities in Pakistan.
 
 - The Company is introducing `Premelle' and `Premelle Cycle', a
 hormone
 replacement therapy (HRT) in India.
 
 - The Company has signed agreements with NSDL, CDSL and Tata
 Consultancy Services, R&T agent, for dematerialisation of the
 company's
 equity shares.
 
 - The Board has apppointed Mr. R.A. Shah as Director and Chairman,
 Mr.
 S. Kumaraswamy as Director.
 
 - The Company to launch in the current year Zosyn, a hospital
 antibiotic for severe infections, and an oncology product, which
 increases the platelet count for patients under chemotherapy
 treatment.
 
 - Wyeth Lederle has launched Premelle and Premelle Cycle, pills
 meant
 for hormone replacement therapy.
 
 2002
 
 -The Wyeth Lederle agreed to amalgamate Geoffrey Manners & Co with
 itself.
 
 -Mr.A.W Khandekar has given his resignation as director of the
 company.
 
 -Wyeth Lederly Ltd has inaugurated its new manufacturing facility at
 Verna, Goa.
 
 -Changes in the Management of Wyeth Lederly:
 1. Mr.Sunil Lalbhai appointed as Additional Director.
 2. Mr.B J Poussot and Mr.H.F Bhabha ceased to be the director.
 3. Mr.M H Bhabha appointed as Alternate to Mr.M M Larsen.
 
 -Wyeth Lederly agreed to amalgamate Geoffrey Manners & Co. with
 itself.
 
 -Wyeth as set up high-tech solid dosage plant at Goa. The company has
 shutdown
 its formulations unit at Ghatkopar in Mumbai
 
 -Wyethe Lederly has shifted its Registered Office to RBC, Mahindra
 Towers, 4thfloor
 A Wing , De G M Bhosale Road, Worli, Mumbai - 400 018.
 
 -Wyeth Lederly has obtained the environment ministry's approval to
 market its
 genetically modified drug Mylotarg, for treating relapse cases of CD
 33 positive
 acute myeloid Leukamia.
 
 2007
 
 - Wyeth Ltd has informed that the Board of Directors of the Company
 at its meeting held on October 27, 2007, has appointed Mr. Ashish
 Dalal, as an Additional Director. Mr. Ashish Dalal is a Non-Executive
 Independent Director.
 
 2009
 
 -The Company has shifted its Registered Office from RBC, Mahindra
 Towers, 4th Floor, 'A' Wing, Dr. G. M. Bhosale Road, Worli, Mumbai
 400 018.The new address is:Level 6 & 7, Platina, Plot No. C - 59, 'G'
 Block, Bandra - Kurla Complex, Bandra (E),Mumbai- 400098.Telephone :
 022 2657 4000 Fax : 022 2657 4100.
 
 -Mr. Kewal Handa was appointed as Additional Director and then as
 Managing Director of the Company.
 
 2010
 
 -Mr. A. W. Khandekar was reappointed as Additional and Whole-time
 Director of the Company.
 
 
 2011
 
 -Wyeth received the Marketing Excellence Award From the Organisation
 of Pharmaceutical Producers of India(OPPI) fo Prevenar in 2010.
 
 -The Goa plant won The Economic Times India Manufacturing Excellence
 Award for 2010.
 
 -Registered Office of the Company has been shifted From Level 6 & 7,
 Platina, Plot No C- 59, G' Block, Bandra - Kurla Complex, Bandra
 (E), Mumbai 400 098 To.Level 6, Platina, Plot No C- 59, G Block,
 Bandra - Kurla Complex, Bandra (E),Mumbai - 400 098
 
 2012
 
 -Wyeth Ltd has appointed Karvy Computershare Private Limited as its
 Registrar and Share Transfer Agent (RTA).
 
 2013
 -Wyeth Ltd has Recommended a dividend of Rs. 17/- per Equity share of
 Rs.10 each (170%) on 2,27,20,059 Equity Shares of Rs. 10/- each.
 -Pfizer Ltd and Wyeth Ltd to Merge, Creating a Single Pfizer Brand.